Fig. 2

TRIM28 inhibition enhances anti-PD-1 therapy in a syngeneic lung cancer model. (A) The schematic of tumor inoculation and treatment in mice. Western blot validated TRIM28 knockout or overexpression in CMT-167 cells. (B) C57BL/6J mice were subcutaneously injected with shControl or shTRIM28 CMT-167 cells and weekly with anti-PD-1 (200 µg/mouse) or isotype control (200 µg/mouse) by intraperitoneal injections starting on day 7 post tumor cell injection. Tumor growth curves and tumor weight were shown. n = 5 mice per treatment group. *p < 0.05; **p < 0.01. (C) C57BL/6J mice were subcutaneously injected with Control or TRIM28 CMT-167 cells and weekly with anti-PD-1 (200 µg/mouse) or isotype control (200 µg/mouse) starting on day 7 post-tumor cell injection. Tumor growth curves and tumor weight were shown. n = 5 mice per treatment group. *p < 0.05; **p < 0.01. (D) Experimental strategy. (E) Humanized huHSC-NOG-EXL mice were injected with shControl or shTRIM28 H1299 cells and treated with anti-PD-1(200 µg/mouse). Control animals were treated with isotype control. Tumor growth curves and tumor weight were shown. The treatment schema is as in (D). n = 5 mice per treatment group. Statistics were calculated using a one-way ANOVA post hoc Tukey test. *p < 0.05; **p < 0.01